Medtronic reports positive IN.PACT Admiral clinical trial data

Medtronic has announced positive data from a new clinical study of its IN.PACT Admiral drug-coated balloon among patients with peripheral artery disease.

The IN.PACT SFA Trialenrolled 331 subjects at 57 sites across Europe and the US and compared the performance of the IN.PACT Admiral drug-coated balloon with standard balloon angioplasty.

It was found that patients with peripheral artery disease in the upper leg who were treated with Medtronic's device experienced significantly better outcomes at 12 months after treatment than those on the alternative therapy regime.

The device has been approved in Europe since 2009, but is yet to receive US clearance. It could become the first drug-coated balloon ratified by the US Food and Drug Administration.

Tony Semedo, senior vice-president at Medtronic and president of the company's endovascular therapies business, said: "We see a path to establishing a new standard of care for SFA disease with an optimised and trusted medical technology."

This comes after the firm also reported positive real-world data demonstrating the benefits provided by its Melody transcatheter pulmonary valve last week.